Savara (SVRA) Deferred Taxes (2018)

Savara's (SVRA) quarterly Deferred Taxes came in at -$2.5 million in Q4 2018, up 45.07% on a QoQ basis from -$4.6 million in Q1 2018.

Savara (SVRA) Deferred Taxes (2018) Analysis & Trends

Savara (SVRA) has 1 years of Deferred Taxes data on file, last reported at -$2.5 million in Q4 2018.

On a quarterly basis, Deferred Taxes changed N/A year-over-year to -$2.5 million in Q4 2018; TTM through Dec 2018 was -$7.1 million, a N/A change from a year earlier, with the FY2018 full-year figure at -$7.1 million, down 150.25% from the prior year.
Deferred Taxes for Q4 2018 stood at -$2.5 million, up from -$4.6 million in the prior quarter.
Over the last five years, Deferred Taxes for SVRA reached as high as -$2.5 million in Q4 2018 and fell as low as -$4.6 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Savara	1.24 Bn	1.24 Bn	-	-

Download Data

Date	Value
Dec 31, 2018	-2.50 Mn
Mar 31, 2018	-4.56 Mn